ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs

SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused …

Do you trust this headline?

Based on recent headline ratings, 100% of this readership currently trusts the local media, which has an average score of 83% regionally and is currently trending positivepositive.


Media Trust Score100%